An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: modeling the cost of treatment strategies in the United States

References

• Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785–1794.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365:1713–1725.
   PubMed Web of Science ®Google Scholar
• Fakhoury M, Negrulj R, Mooranian A, et al. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res. 2014;7:113–120.
   PubMedGoogle Scholar
• Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501–523.
   PubMed Web of Science ®Google Scholar
• Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571–607.
   PubMed Web of Science ®Google Scholar
• Farthing M, Roberts SE, Samuel DG, et al. Survey of digestive health across Europe: final report. Part 1: The burden of gastrointestinal diseases and the organisation and delivery of gastroenterology services across Europe. United Eur Gastroenterol J. 2014;2:539–543.
   PubMed Web of Science ®Google Scholar
• Cohen RD, Yu AP, Wu EQ, et al. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther. 2010;31:693–707.
   PubMed Web of Science ®Google Scholar
• Null KD, Xu Y, Pasquale MK, et al. Ulcerative colitis treatment patterns and cost of care. Value Health. 2017;20:752–761.
   PubMed Web of Science ®Google Scholar
• Park SC, Jeen YT. Current and emerging biologics for ulcerative colitis. Gut Liver. 2015;9:18–27.
   PubMed Web of Science ®Google Scholar
• Bressler B, Marshall JK, Bernstein CN, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterol. 2015;148:1035–1058.e3.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367:616–624.
   PubMed Web of Science ®Google Scholar
• Sandborn W, Sands BE, D’Haens GR, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–1736.
   PubMed Web of Science ®Google Scholar
• Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5:1424–1429.
   PubMed Web of Science ®Google Scholar
• Claxton L, Jenks M, Taylor M, et al. An economic evaluation of tofacitinib treatment in rheumatoid arthritis: modeling the cost of treatment strategies in the United States. JMCP. 2016;22:1088–1102.
   PubMedGoogle Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476.
   PubMed Web of Science ®Google Scholar
• Jiang XL, Cui HF, Gao J, et al. Low-dose infliximab for induction and maintenance treatment in Chinese patients with moderate to severe active ulcerative colitis. J Clin Gastroenterol. 2015;49:582–588.
   PubMed Web of Science ®Google Scholar
• Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003;52:998–1002.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Motoya S, Hirai F, et al. Infliximab therapy for Japanese patients with ulcerative colitis: efficacy, safety, and association between serum infliximab levels and early response in a randomized, double-blind, placebo-controlled study. J Crohns Colitis. 2015;9:S372–S373.
   Web of Science ®Google Scholar
• Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257–265 e1–3.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60:780–787.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Motoya S, Hanai H, et al. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol. 2014;49:283–294.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146:85–95. quiz e14–15.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699–710.
   PubMed Web of Science ®Google Scholar
• Xeljanz (tofacitinib) Prescribing Information. New York (NY); Pfizer, Inc.; 2012. (Revised May 2018). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203214s018lbl.pdf. [Accessed 2018 July 6].
   Google Scholar
• Remicade (infliximab) Prescribing Information. Horsham (PA); Janssen Biotech, Inc.; 2013. (Revised October 2017). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103772s5359lbl.pdf [Accessed 2018 July 6].
   Google Scholar
• Humira (adalimumab) Prescribing Information. North Chicago (IL); Abbott Laboratories Inc. 2013. (Revised December 2017). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125057s0276lbl.pdf [Accessed 208 July 6].
   Google Scholar
• Simponi (golimumab) Prescribing Information. Horsham (PA.) Janssen Biotech Inc. 2014. (Revised May 2018). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125289s0064lbl.pdf [Accessed 2018 July 6].
   Google Scholar
• Entyvio (vedolizumab) Prescribing Information. Deerfield (IL); Takeda Pharmaceuticals America, Inc.; 2014. (Revised February 2018). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125476s000lbl.pdf [Accessed 2018 July 6].
   Google Scholar
• Bickston SJ, Waters HC, Dabbous O, et al. Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients. JMCP. 2008;14:352–362.
   PubMed Web of Science ®Google Scholar
• Holubar SD, Long KH, Loftus EV, et al. Long-term direct costs before and after proctocolectomy for ulcerative colitis: a population-based study in Olmsted County, Minnesota. Dis Colon Rectum. 2009;52:1815–1823.
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Herfarth H, Katz J, et al. American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases. Gastroenterology. 2017;153:835–857.e6.
   PubMed Web of Science ®Google Scholar
• Analysource® (Selected from FDB MedKnowledge (formerly known as NDDF Plus) data included with permission and copyrighted by First Databank, Inc.). 2018. Available from: https://www.analysource.com/ [Accessed 2018 July 6].
   Google Scholar
• Rubin D, Mody R, Davis K, et al. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease. Aliment Pharmacol Ther. 2014;39:1143–1155.
   PubMed Web of Science ®Google Scholar
• InGauge Healthcare Solutions. Physician’s Fee and Coding Guide. Atlanta (GA): InGauge Publications; 2017.
   Google Scholar
• Dias S, Ades AE, Welton NJ, et al. Network Meta-Analysis for Decision-Making. Chichester (UK): John Wiley & Sons Ltd, 2018.
   Google Scholar
• Singh S, Fumery M, Sandborn WJ, et al. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47:162–175.
   PubMed Web of Science ®Google Scholar
• Bonovas S, Lytras T, Nikolopoulos G, et al. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47:454–465.
   PubMed Web of Science ®Google Scholar
• Rubin DT, Ashaye AO, Zhang Y, et al. Efficacy of tofacitinib and biologics as induction and maintenance therapy for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Poster presented at the American College of Gastroenterology congress; 2018 October; Philadelphia, PA.
   Google Scholar
• Wu B, Wang Z, Zhang Q. Cost-effectiveness of different strategies for the treatment of moderate-to-severe ulcerative colitis. Inflamm Bowel Dis. 2018;24:2291–2302.
   PubMed Web of Science ®Google Scholar